Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours Β· Estimated delivery Aug 16 - Aug 21
503A pharmacy sourced, tested, and prescription-grade
Helps reduce fatigue
For example, the FDAs approval of Lillys ZepBound (tirzepatide for chronic weight management) in late 2023 was based on phase III data showing superior weight loss compared to placebo
After 72 weeks: Participants taking 5 mg of tirzepatide lost 15% of their starting body weight on average Those taking 10 mg lost an average of 19.5% Those taking the highest dose, 15 mg, lost an average of 20.9% Another phase 3 clinical trial studied the efficacy of once-daily orforglipron in people with obesity and found that it resulted in significant weight loss compared to placebo
This policy is designed as a temporary measure to ensure continuity of care when FDA-approved drugs are not commercially available
US$ 24.46
US$ 21.28
US$ 24.82
US$ 25.72
US$ 21.78
US$ 22.27
US$ 24.14
US$ 27.68
US$ 29.84
US$ 23.00
US$ 27.11
US$ 23.04
US$ 28.82
US$ 23.33
US$ 24.79
